Huntington's Disease Drug Works - Memantine (Namenda®)

Trial status: Still enrolling at Johns Hopkins University and the University of Kansas. Enrollment is complete at the University of California-San Diego.

Trial name: Memantine in Huntington's

FDA phase: Phase III for Huntington's. This drug is already FDA-approved for Alzheimer's.

Sponsor: Forest Pharmaceuticals, Inc.

Trial design: Seventy-two people altogether will participate in a 6-month trial. During the first 3 months, half will receive memantine (10 mg, twice daily), and the other half placebo. During the remaining 3 months, all will receive memantine.

Outcome measures: Outcome measures compare short-term memory and cognition before and after treatment.

Location: University of California-San Diego, University of Kansas, and Johns Hopkins University.

Contact information: Please contact Abhijit Agarwal by phone at 1-410-955-1349, by mail at 600 North Wolfe Street, Meyer 2-181, Baltimore, MD 21287, or by email at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

< Prev		Next >

[ Back ]